Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 January, 2018 04:11 IST
Glenmark Pharma aims to transform Psoriasis treatment in India
Source: IRIS | 13 Nov, 2017, 11.36AM
Comments  |  Post Comment

Glenmark Pharmaceuticals, a research-led global integrated pharmaceutical company, announced the launch of Apremilast in India. Apremilast is the first advanced Oral Systemic treatment for Psoriasis in India. Apremilast is a phosphodiesterase 4 (PDE4) inhibitor which is indicated for the treatment of moderate to severe Psoriasis. The launch of Apremilast will revolutionize the treatment of Psoriasis impacting close to 33 million Indians suffering from the condition.
 
Apremilast is an advanced oral treatment for Psoriasis which addresses the limitations of the current available therapies in India. It acts in a targeted manner at an early stage of the disease progression. Also, it is an immunomodulator whereas the other available drugs in the country are immunosuppressant including biologics and are mostly indicated for the treatment of oncological conditions. Immunosuppressants suppress the immune system thereby making the body susceptible to various infections. Apremilast being an immunomodulator does not suppress the immune system and treats the condition of psoriasis at an intracellular level which will benefit psoriasis patients across the country.
 
Apremilast is an oral therapy which can be self-administered unlike some of the currently available injectable therapy which have to be administered by paramedics. Further, Apremilast is a safer drug having no effects on other organs like the liver and kidney and does not require routine laboratory diagnostic tests like CBC, liver & Kidney test or TB screening as required in the case of other therapies used currently.
 
Glenmark has launched Apremilast under the brand name 'Aprezo' indicated for the treatment of Psoriasis. Glenmark (Q,N,C,F)* received approval from DCGI for Apremilast after conducting clinical trials on the molecule as per the regulatory requirements.

Shares of the company declined Rs 13.15, or 2.22%, to trade at Rs 579.50. The total volume of shares traded was 24,361 at the BSE (11.17 a.m., Monday).

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Reliance Q3 profit up 25.5%; GRM at USD 11.6/bbl - 19-Jan-2018 18:34
HDFC Bank Q3 net grows 20% to Rs 41.51 bn - 19-Jan-2018 18:07
Wipro Q3 earnings fall 12% q-o-q to Rs 19.3 bn - 19-Jan-2018 17:56
Lupin launches generic Vibra-Tabs tablet in US - 19-Jan-2018 15:56
HCL Tech Q3 profit jumps 6% to Rs 21.94 bn - 19-Jan-2018 11:45
Suven Life Sciences secures 2 overseas product patents - 18-Jan-2018 15:26
Yes Bank Q3 profit rises 22% to Rs 10.76 bn - 18-Jan-2018 15:24
Sanghvi Forging & Engg bags new orders worth Rs 110 mn - 18-Jan-2018 10:17
Tata Consultancy Services expands partnership with Shure Inc - 18-Jan-2018 10:13
Ashok Leyland signs Lol with Phinergy, Israel for high energy EV - 17-Jan-2018 16:20
Transformers & Rectifiers India receives Rs 1.26 bn order - 17-Jan-2018 16:05
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer